Rokit Healthcare's Dr. Invivo bio printer prints skin grafts from patient's own cells

Rokit Healthcare, a South Korean bio 3D printing specialist, is drawing significant investor attention as its regenerative medicine platform gains clinical traction. The company's Dr. Invivo bioprinter, combined with AI-based genetic analysis, scans a patient's wound, calculates the defect geometry, and prints a custom tissue patch using the patient's own adipose-derived bio-ink. This approach targets chronic non-healing wounds such as diabetic foot ulcers and pressure sores, where standard treatments often fail.

The company has secured medical device approvals in dozens of countries and is building a global clinical evidence base for its point-of-care manufacturing model. Rather than printing generic scaffolds, Rokit's system produces living tissue grafts tailored to each patient's anatomy and cellular profile, which could shift the treatment paradigm for hard-to-treat skin defects. The platform integrates hardware, software, and biological materials into a single regulated workflow, a combination that remains rare in commercial bioprinting.

Rokit's progress illustrates how bioprinting is moving from academic curiosity toward regulated clinical deployment, but the gap between regulatory clearance and widespread hospital adoption remains wide. The company must demonstrate that its point-of-care workflow can be reliably reproduced across different clinical settings, not just in controlled trial environments. For investors, the distinction between a promising technology platform and a scalable medical device business is still being tested.